Lawsuit Alleges Misleading Data on RGX-111 Gene Therapy
REGENXBIO Inc. (NASDAQ: RGNX) is the target of a securities fraud lawsuit alleging the company concealed material adverse facts about its product candidate, RGX-111. The one-time gene therapy is being developed to treat severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. According to the lawsuit, REGENXBIO made overwhelmingly positive statements to investors regarding the future success of the RGX-111 trial, citing ongoing positive biomarker and safety data from its Phase I/II study. The complaint argues these assertions were false and misleading, as the company allegedly failed to disclose negative information concerning the therapy's true efficacy and safety profile.
Class Action Covers Nearly Four-Year Period of Statements
The class-action lawsuit, filed in federal court, includes all investors who purchased or acquired REGENXBIO securities between February 9, 2022, and January 27, 2026. Law firms, including Faruqi & Faruqi, LLP and The Rosen Law Firm, are reminding affected investors of the April 14, 2026, deadline to move the court to be appointed as a lead plaintiff. A lead plaintiff is a representative party that acts on behalf of all other class members in directing the litigation. The lawsuit claims that when the true details about RGX-111's trial performance eventually entered the market, investors suffered financial damages.
Legal Battle Creates Financial Overhang for RGNX
This legal challenge introduces significant uncertainty for REGENXBIO and its shareholders. The defense against a securities class action can result in substantial litigation costs and divert management's attention from core business operations. If the company is found liable or chooses to settle, it could face considerable financial penalties. The allegations risk eroding investor confidence, which could apply negative pressure on the RGNX stock price as the case proceeds.
